Cartilage damage in the knee affects millions of people worldwide with a continued rise in incidence. Currently, the only conventional solutions are symptoms (pain, stiffness) management, microfracture and in the end, replacing the joint with a prosthesis. Lately, cell therapies have emerged as a solution to regenerate cartilage e.g. tissue engineered autologous chondrocyte implantations (ACIs). However, ACIs often fail to integrate with the surrounding tissue, which results in failure rates up to 36%. Lamina’s new cell therapy from the Strasbourg University and Inserm aims to improve the cell approach by an innovative scaffold that houses Mesenchymal stem cells (MSCs) for optimal regeneration of the cartilage. By combining this patented scaffold together with growth factors and the MSCs, the product ensures fast recovery and high quality cartilage.
Recent news
INTRODUCING CONCORD BIRTH FLOW: BUILDING THE FUTURE OF CHILD BIRTH
PRESS RELEASE November 8, 2022 St. Antonius Hospital in the Netherlands leading the way with the Concord Birth Flow St. Antonius Hospital is the…
Read more
MINDAFFECT SELECTED FOR POLE POSITION PROGRAMME
October 11, 2022 PRESS RELEASE MindAffect selected for Pole Position Programme – DeepTech/Medical field MindAffect, a BCI/AI Healthtech company specializing in the development of…
Read more
INTRODUCING CRAINIO: REVOLUTIONISING THE MEASUREMENT OF INTRACRANIAL PRESSURE
PRESS RELEASE October 5, 2022 Crainio, an NLC venture, sets out to revolutionise the measurement of intracranial pressure (ICP) by developing a non-invasive measuring…
Read more